Glucocorticoids have been used in the treatment of prostate cancer to slow disease progression, improve pain control and offset side effects of chemo- and hormonal therapy.
However, they may also have the potential to drive prostate cancer growth via mutated androgen receptors or glucocorticoid receptors (GRs). In this review we examine historical and contemporary use of glucocorticoids in the treatment of prostate cancer, review potential mechanisms by which they may inhibit or drive prostate cancer growth, and describe potential means of defining their contribution to the biology of prostate cancer.
View full text article:
Written by:
Bruce Montgomery,1 Heather H Cheng,1 James Drechsler,2 and Elahe A Mostaghel3 Are you the author?
1Department of Medicine, University of Washington, Seattle
2Seattle Cancer Care Alliance, Seattle
3Division of Clinical Research, Fred Hutchinson Cancer Research
Center, Seattle, Washington, USA.
Reference:Asian J Androl. 2014 May-Jun;16(3):354-8
doi: 10.4103/1008-682X.125392
PubMed Abstract
PMID: 24625881
UroToday.com Prostate Cancer Section
